Low dose naltrexone
Low Dose Naltrexone (LDN) refers to very small doses of the drug naltrexone hydrochloride, which is normally used to treat drug or alcohol dependence. When taken at much smaller doses naltrexone may reduce pain, or potentially neurological symptoms. Brand names of naltrexone include ReViva, Depade, and Vivitrol. LDN use other for treating drug dependence is considered off-label. Some patients report that LDN helps reduce their symptoms of ME/CFS, multiple sclerosis (MS), fibromyalgia (FMS), or autoimmune disease. Although its mechanism of action is unclear, some have speculated that it may act as an anti-inflammatory.
- 1 Perscription forms
- 2 VLDN and ULDN
- 3 Evidence
- 4 News articles
- 5 Clinical use
- 6 Pharmacies
- 7 Clinical trials
- 8 When, How To Take
- 9 Talks and webinars
- 10 Notable studies
- 11 See also
- 12 Learn more
- 13 References
Perscription forms[edit | edit source]
LDN is typically prescribed using generic naltrexone hydrochloride or branded naltrexone, divided into much smaller doses. LDN may be taken in the form of liquid solution/syrup, sublingual doses or 1.5mg capsules, or a compounding pharmacy can create smaller sized capsules or tablets. LDN in the form of naltrexone cream, subcutaneous injections, IV naltrexone and eye drops (for dry eyes) are also available.
VLDN and ULDN[edit | edit source]
Very Low Dose Naltrexone (VLDN) and Ultra-Low Dose Naltrexone (ULDN) have recently been used in limited trials, both VLDN and ULDN involve doses of naltrexone significantly below 1mg.
Evidence[edit | edit source]
A 2014 review by Stanford researchers suggests that "LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone's better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated."
The FDA approved naltrexone HCL in 1984 to treat opioid addiction. Low-dose naltrexone is typically given at about 1/10th the typical dose of naltrexone. By blocking opioid receptors, naltrexone can increase pain, but at very low doses naltrexone has both pain-reducing (analgesic) and anti-inflammatory properties.
In 2012 Solve ME/CFS Initiative contracted Biovista to use drug models to identify existing drugs that may be worth investigating for treatment. The results suggested Naltrexone was worth considering.
Jarred Younger's research suggests that people with an Erythrocyte Sedimentation Rate (ESR) over 40 millimeters an hour, tend to be strong responders to LDN, and that there may be other predictive factors for success.
News articles[edit | edit source]
- 2019, In Tiny Doses, An Addiction Medication Moonlights As A Treatment For Chronic Pain - NPR, All Things Considered
Clinical use[edit | edit source]
Naltrexone is a prescription drug in many countries including the United States.Compounding chemists or compounding pharmacists can mix naltrexone with a powder filler or dilute in into a liquid to create the lower dose.
Fast-release fillers only[edit | edit source]
The LDN Research Trust advises that: "Pharmacies should be instructed NOT to provide LDN in an "SR" or slow-release or timed-release form. Unless the low dose of naltrexone is in an unaltered form, which permits it to reach a prompt "spike" in the blood stream, its therapeutic effects may be inhibited." and states that calcium carbonate filler should NOT be used because they reduce absorption, instead Avicel, lactose, or sucrose fillers as alternative fast-release fillers."
Do not take with[edit | edit source]
In general, Low Dose Naltrexone (LDN) should not be taken concurrently with opioid-containing drugs (opioid receptors in brain are blocked by LDN), alcohol, immunosuppressive drugs, or immunomodulator drugs. LDN blocks the effect of opioid drugs. Some opioid drugs are codeine, tramadol, oxycodone, vicodin, hydrocodone, fentanyl and morphine.
Pharmacies[edit | edit source]
Australia[edit | edit source]
Compounding Pharmacies are able to fill these prescriptions, and post if needed.
UK[edit | edit source]
LDN suppliers in the UK include Dickson Chemist in Glasgow, Roseway Labs, and Specialist Pharmacy (The London Specialist Pharmacy Ltd). All these are compounding pharmacies and require a perscription, they are usually able to put patients in contact with private doctors who will consider writing a prescription, and can post medications to you. Compounding pharmacies are regulated by the UK's General Pharmaceutical Council.
United States[edit | edit source]
Neighborhood Compounding Pharmacies are able to fill these prescriptions and mail if needed. Your prescribing doctor can help you locate a compounding pharmacy in your area/state or you can look online.
Other countries[edit | edit source]
The LDN Research Trust lists pharmacies in multiple countries.
Clinical trials[edit | edit source]
A large number of clinical trials have been completed for LDN recently, although none have looked at the effect of LDN on symptoms of myalgic encephalomyelitis/chronic fatigue syndrome. Research has been carried out on patients with MS, Chronic Regional Pain Syndrome, FMS, Irritable Bowel Syndrome (IBS), Ulcerative Colitis, Skin Disorders and a range of other illnesses.
When, How To Take[edit | edit source]
Dr Whitaker states that the ideal dose is different for each person. Some doctors recommend starting at 1mg. Common dosages are 1.5mg, 3mg, 4.5mg. When beginning use of LDN, the drug must be stepped up over 6-8+ weeks as it may keep you awake; discuss how best to do this with your doctor and pharmacist.
Talks and webinars[edit | edit source]
Notable studies[edit | edit source]
- 2009, Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study - (Full text)
- 2013, Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels - (Full text)
- 2014, The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain - (Full text)
- 2018, Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness - (Abstract)
- 2019, Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) - (Abstract)
- 2020, Low-dose naltrexone as a treatment for chronic fatigue syndrome - (Full text)
See also[edit | edit source]
Learn more[edit | edit source]
- Low-dose Naltrexone (LDN) Doctor's Fact Sheet 2014 - LDN Research Trust
- LDN Research Trust
- Low Dose Naltrexone and chronic pain
- Wikipedia - Naltrexone
- LDN Now
- LDN Science - MedInsight Research Institute
- 2015, The Use of Naltrexone in Low Doses Beyond the Approved Indication
- Top 15 Scientific Health Benefits of Low Dose Naltrexone (2016)
- Low Dose Naltrexone Resource Center for Fibromylgia and ME/CFS (2019)
- 2016, Low-Dose Naltrexone as Adjunctive Pharmacotherapy for Fibromyalgia
- The LDN Book - Lisa Elsegood (2016)
- 2016, Low Dose Naltrexone Drug Combination Proposed for Chronic Fatigue Syndrome, Health Rising, by Cort Johnson (2016)
- Low dose naltrexone: side effects and efficacy in gastrointestinal disorders by CFS Remission (2016)
- Opioid blocking and alcohol - FAQ About Naltrexone Treatment for Alcoholism - 10.
- Low Dose Naltrexone for Fibromyalgia (2018)
- Low Dose Naltrexone Therapy for Crohn’s Disease (2018)
References[edit | edit source]
- "Naltrexone - brand name list from Drugs.com". Drugs.com. Retrieved January 17, 2022.
- Younger, Jarred; Parkitny, Luke; McLain, David (February 15, 2014), "The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain", Clin Rheumatol, 33 (4): 451-459, doi:10.1007/s10067-014-2517-2, PMID 24526250
- "Types of LDN". LDN Research Trust. Retrieved January 17, 2022.
- Toljan, Karlo; Vrooman, Bruce (September 21, 2018). "Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization". Medical Sciences. 6 (4). doi:10.3390/medsci6040082. ISSN 2076-3271. PMID 30248938.
- Younger, Jarred; Mackey, Sean (April 22, 2009), "Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study", Pain Med, 10 (4): 663–672, doi:10.1111/j.1526-4637.2009.00613.x, PMID 2891387
- Mackey, Sean (May 1, 2009), "An Update on Fibromyalgia", Research Channel (USA)
- Younger, Jarred; Noor, Noorulain; McCue, Rebecca; Mackey, Sean (January 28, 2013), "Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels", Arthritis Rheum, 65 (2): 529-38, doi:10.1002/art.37734, PMID 23359310
- "Low Dose Naltrexone for Fibromyalgia". Systems Neuroscience and Pain Lab | Stanford Medicine. Retrieved October 4, 2018.
- Solve ME/CFS Initiative. "Biovista work released".
- Younger, Jarred; Cohen, Joseph M (March 29, 2016), "Dr. Jarred Younger: Cutting Edge Research on CFS, Neuroinflammation, Pain, and Fatigue", Self Hacked Blog (video interview with transcript)
- Feeney, G. F. X.; Connor, J. P.; Young, R. McD; Tucker, J.; Czajkowski, F. (2001). "Adherence with naltrexone prescription advice in hospital outpatient alcohol rehabilitation programme". Journal of Clinical Pharmacy and Therapeutics. 26 (1): 73–79. doi:10.1111/j.1365-2710.2001.00326.x. ISSN 1365-2710.
- "Low-dose Naltrexone (LDN) Fact Sheet 2014" (PDF). LDN Research Trust. 2014.
- "Drugs To Avoid When Taking Low Dose Naltrexone". Yourverity's Blog. July 7, 2009. Retrieved March 17, 2021.
- Chopra, Pradeep. "Low Dose Naltrexone and chronic pain". LDN Research Trust. Retrieved January 31, 2019.
- Finding a Compounding Pharmacy - WIKI How
- "Clinical Trials". LDN Research Trust. Retrieved January 21, 2019.
- LDN Now. "LDN Dosing". Retrieved February 1, 2018.
- Myers, Amy (May 2, 2017). "Low-Dose Naltrexone for Autoimmunity?". Amy Myers MD. Retrieved February 2, 2019.
- Dr Whitaker. "What is Low-Dose Naltrexone?". www.drwhitaker.com. Retrieved January 21, 2019.
- Cite error: Invalid
<ref>tag; no text was provided for refs named
- "Low Dose Naltrexone (LDN) – Collier Drug Store". collierdrug.com. What dose of Low Dose Naltrexone (LDN) is best?. Retrieved February 2, 2019.
- "LDNscience® Presents - How LDN (Low Dose Naltrexone) Works". YouTube. LDNscience. December 20, 2012.
- Carnahan, Jill; Vasquez, Alex (November 30, 2015). "Functional Medicine & LDN (low-dose naltrexone) with Drs Carnahan and Vasquez". YouTube. Alex Vasquez.
- "1:05 / 7:05 Is Low Dose Naltrexone (LDN) for you?". YouTube. October 11, 2015.
- Younger, Jarred; Mackey, Sean (May 2009). "Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study". Pain Medicine. 10 (4): 663–672. doi:10.1111/j.1526-4637.2009.00613.x. ISSN 1526-2375. PMC 2891387. PMID 19453963.
- Brewer, Kori L.; Mainhart, Allison; Meggs, William J. (2018), "Double-blinded placebo-controlled cross-over pilot trial of naltrexone to treat Gulf War Illness", Fatigue: Biomedicine, Health & Behavior, doi:10.1080/21641846.2018.1477034
- Toljan, Karlo; Vrooman, Bruce (September 21, 2018). "Low-Dose Naltrexone (LDN)—Review of Therapeutic Utilization". Medical Sciences. 6 (4): 82. doi:10.3390/medsci6040082. ISSN 2076-3271. PMC 6313374. PMID 30248938.
- Polo, Olli; Pesonen, Pia; Tuominen, Essi (November 19, 2019). "Low-dose naltrexone in the treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)". Fatigue: Biomedicine, Health & Behavior: 1–11. doi:10.1080/21641846.2019.1692770. ISSN 2164-1846.
- Bolton, Monica Jane; Chapman, Bryan Paul; Van Marwijk, Harm (January 2020). "Low-dose naltrexone as a treatment for chronic fatigue syndrome". BMJ Case Reports. 13 (1): e232502. doi:10.1136/bcr-2019-232502. ISSN 1757-790X. PMC 6954765. PMID 31911410.
- "LDN Research Trust - Low Dose Naltrexone |". www.ldnresearchtrust.org. Retrieved February 2, 2019.
- Ringerike, Tove; Pike, Eva; Nevjar, Janicke; Klemp, Marianne (2015), The Use of Naltrexone in Low Doses Beyond the Approved Indication, NIPH
subcutaneous "being, living, occurring, or administered under the skin"
double blinded trial A clinical trial is double blinded if neither the participants nor the researchers know which treatment group they are allocated to until after the results are interpreted. This reduces bias. (Learn more: www.nottingham.ac.uk)